Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Cash from Investing Activities (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Cash from Investing Activities for 8 consecutive years, with -$125.4 million as the latest value for Q4 2025.

  • For Q4 2025, Cash from Investing Activities changed N/A year-over-year to -$125.4 million; the TTM value through Dec 2025 reached -$201.8 million, changed N/A, while the annual FY2025 figure was -$201.8 million, 10.59% up from the prior year.
  • Cash from Investing Activities hit -$125.4 million in Q4 2025 for Soleno Therapeutics, down from -$91.4 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $22.9 million in Q1 2025 and bottomed at -$125.4 million in Q4 2025.